Together, these studies underscore the critical role of B cells and their interaction with the TNF pathway in HS pathogenesis, highlighting the potential of a novel nanobody targeting both OX40L and TNF (ClinicalTrials.gov NCT05849922) as a promising therapeutic approach. This evidence concerns the gene TNF and histiocytic sarcoma.